Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.56 |
| ▸ | DRD4 | P21917 | 4/20 | 0.56 |
| ▸ | DRD3 | P35462 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 7/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 7/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19852214 | 1.00 | DRD2 (0.56) | DRD2DRD4DRD3TSHRMEN1 | |
| SCHEMBL21071707 | 1.00 | DRD2 (0.56) | DRD2DRD4DRD3TSHRMEN1 | |
| SCHEMBL21071969 | 1.00 | DRD2 (0.56) | DRD2DRD4DRD3TSHRMEN1 | |
| SCHEMBL21071709 | 1.00 | DRD2 (0.56) | DRD2DRD4DRD3TSHRMEN1 | |
| SCHEMBL21071533 | 0.94 | DRD2 (0.49) | DRD2DRD4DRD3TSHRMEN1 | |
| SCHEMBL21071534 | 0.94 | DRD2 (0.49) | DRD2DRD4DRD3TSHRMEN1 | |
| SCHEMBL21071868 | 0.94 | DRD2 (0.49) | DRD2DRD4DRD3TSHRMEN1 | |
| SCHEMBL21071536 | 0.94 | DRD2 (0.49) | DRD2DRD4DRD3TSHRMEN1 | |
| SCHEMBL21071528 | 0.94 | DRD2 (0.49) | DRD2DRD4DRD3TSHRMEN1 | |
| SCHEMBL21071527 | 0.94 | DRD2 (0.49) | DRD2DRD4DRD3TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | DRD2 69/4885DRD4 237/4885DRD3 290/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | DRD2 69/4885DRD4 237/4885DRD3 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.